Dispensing of Antiemetics During Pregnancy in Aotearoa New Zealand, 2005–2020
Open Access
- 17 June 2026
- journal article
- Published by Wiley in Australian and New Zealand Journal of Obstetrics and Gynaecology
- Vol. 66 (3) , e70157
Abstract
Background: Antiemetic use during pregnancy is rising in high‐income countries. Increasing use of antiemetics has also been documented in Aotearoa New Zealand (NZ); however, the specific antiemetics dispensed have not been reported. Aim: To describe patterns of antiemetic dispensing during pregnancy in NZ, 2005–2020. Materials and Methods: Community‐based antiemetic dispensings were linked with 1.37 million pregnancies in the New Zealand Pregnancy Cohort. The proportions of pregnancies in which there was at least one dispensing of any and of specific antiemetics were calculated for each trimester and calendar year. Maternal characteristics and the sequence in which unique antiemetic regimens were introduced were described for pregnancies with first trimester exposure. Results: First trimester antiemetic exposure increased from 4.1% to 19.7% of pregnancies between 2005 and 2019. Although metoclopramide was the most commonly dispensed antiemetic during Trimester 1 in all years (increasing from 3.1% to 12.4%), there was a substantial increase in ondansetron dispensing (0.1% to 9.1%). Ondansetron users were more likely than metoclopramide users to be European/Other and have a hospital admission for hyperemesis gravidarum. Metoclopramide and ondansetron monotherapy were first‐line regimens in 70.0% and 1.9% of pregnancies with Trimester 1 exposure between 2005 and 2010 versus 46.5% and 26.5% between 2016 and 2020. Conclusions: Ondansetron dispensing increased substantially over time. Further exploration of the context of ondansetron prescribing in NZ is warranted, as is further research into potential adverse outcomes.Keywords
Funding Information
- Health Research Council of New Zealand (21/279/A)
This publication has 32 references indexed in Scilit:
- Quantifying the global rates of nausea and vomiting of pregnancy: a meta analysis.2013
- Ondansetron in Pregnancy and Risk of Adverse Fetal OutcomesNew England Journal of Medicine, 2013
- A survey of prescribing for the management of nausea and vomiting in pregnancy in AustralasiaAustralian and New Zealand Journal of Obstetrics and Gynaecology, 2013
- Medications used to treat nausea and vomiting of pregnancy and the risk of selected birth defectsBirth Defects Research Part A: Clinical and Molecular Teratology, 2011
- Causes of excess hospitalisations among Pacific peoples in New Zealand: implications for primary careJournal of Primary Health Care, 2010
- Nausea and vomiting in pregnancy: maternal characteristics and risk factorsPaediatric and Perinatal Epidemiology, 2006
- Placental Transfer of Ondansetron during Early Human PregnancyClinical Pharmacokinetics, 2006
- A Modified Poisson Regression Approach to Prospective Studies with Binary DataAmerican Journal of Epidemiology, 2004
- Relationship between vitamin use, smoking, and nausea and vomiting of pregnancy.2003
- Longitudinal Data Analysis for Discrete and Continuous OutcomesBiometrics, 1986